| MM | MGUS and SMM | NPC |
---|---|---|---|
(n) | (n) | (n) | |
Total | 20 | 7 | 15 |
 Male | 12 | 2 | 12 |
 Female | 8 | 5 | 3 |
Range of age (years) | 32–75 | 54–72 | 38–76 |
ISS | Â | Â | Â |
 Stage I | 4 |  |  |
 Stage II | 1 |  |  |
 Stage III | 13 |  |  |
Type of monoclonal component | Â | Â | Â |
 IgG, κ | 10 | 3 |  |
 IgG, λ | 1 | 2 |  |
 IgA | 2 | 1 |  |
 Light chain | 7 | 1 |  |
 Non-secretory | 0 |  |  |
β2 microglobulin | 5.8 |  |  |
Median number of prior regimens | 2 | Â | Â |
Auto HSCT | 3 | Â | Â |
Prior bortezomib | 14 | Â | Â |
Prior lenalidomide | 9 | Â | Â |
Prior thalidomide | 2 | Â | Â |